TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04162145

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active BRIDGE device placement
Description: The active BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive BRIDGE device placement
Description: The inactive or sham BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
Study: NCT02855996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fathers in Action/Padres Activos (FA/PA) program
Description: The program focuses on increasing the father's role in the child's education, nurturing and bonding with the child, loving and respecting the child's mother, coaching the child, and serving as a role model. The program also includes employment coaching.
Study: NCT01220479

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Exercise training program
Description: Exercise Diabetic and Healthy groups perform a similar training program including two exercise sessions per week, of 90 minutes each, during 9 months (excluding holidays) under supervision by physical education teachers and pediatricians. Sessions comprise various weight-bearing activities: rope skipping, jumping, ball games and gymnastics.~Control groups are relatively inactive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: Exercise Diabetic and Healthy groups perform a similar training program including two exercise sessions per week, of 90 minutes each, during 9 months (excluding holidays) under supervision by physical education teachers and pediatricians. Sessions comprise various weight-bearing activities: rope skipping, jumping, ball games and gymnastics.~Control groups are relatively inactive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: Exercise Diabetic and Healthy groups perform a similar training program including two exercise sessions per week, of 90 minutes each, during 9 months (excluding holidays) under supervision by physical education teachers and pediatricians. Sessions comprise various weight-bearing activities: rope skipping, jumping, ball games and gymnastics.~Control groups are relatively inactive.
Study: NCT06274541

Intervention type: GENETIC
Intervention: Somatic and Germline BRCA1/2 Testing
Description: Germline BRCA1/2 mutation testing will be undertaken by NGS using blood samples. Somatic BRCA1/2 mutation testing will be undertaken by NGS using tumour tissue.
Study: NCT05505513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous Utah Slanted Electrode Arrays (pUSEAs)
Description: Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations.
Study: NCT03427359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin, capecitabine
Description: Experimental arm patients received 3 cycles of induction chemotherapy (cisplatin 80mg/m2, day 1; oral capecitabine 1000mg/m2 twice daily from day1-14, repeated every 3 weeks) followed by concomitant cisplatin (100mg/m2,day1,every 3 weeks) for a total of 2 cycles with radiotherapy.
Study: NCT03725189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPG during exercise
Description: PPG use for pulse waveform evaluation of healthy exercise group
Study: NCT00003120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 135 mg/m2 IV every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 135 mg/m2 IV every 28 days
Study: NCT04220294

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous tissue closure
Description: Subcutaneous tissue closure with 2-0 vicryl suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous tissue closure
Description: Subcutaneous tissue closure with 2-0 vicryl suture.
Study: NCT04421911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen topical
Description: Ketoprofen topical for 21days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Topical
Description: Diclofenac topical for 21days
Study: NCT05066516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCDP, dapagliflozin 10mg/linagliptin 5 mg or co-administration of a single dose of dapagliflozin and linagliptin
Description: FCDP, dapagliflozin 10mg/linagliptin 5 mg or ICs, co-administration of a single dose of dapagliflozin and linagliptin
Study: NCT03229265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: Patiromer (8.4 grams) will be taken daily at 3 hours after oral tacrolimus and MMF dosing by subjects commencing 3 days (± 1 day) prior to visit 1.
Study: NCT02850458

Intervention type: DEVICE
Intervention: implant-retained overdentures
Description: patients treated with an implant-retained overdenture in the mandible

Intervention type: DEVICE
Intervention: implant-retained overdentures
Description: patients treated with an implant-retained overdenture in the mandible
Study: NCT02261636

Intervention type: DRUG
Intervention: mesalazine
Study: NCT00149916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium (enteric coated)
Study: NCT01063764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: First Period: Dry syrup 50 %, 20 mg/kg/day or 1000 mg/day, 40 mg/kg/day or 2000 mg/day, 60 mg/kg/day or 3000 mg/day, twice daily administration Per Os (PO) for 14 weeks.~Second Period: Dry syrup 50 % or tablets (250 mg and 500 mg strengths), 20 to 60 mg/kg/day or 1000 to 3000 mg/day, twice daily administration Per Os (PO) until indication granted.
Study: NCT03244865

Intervention type: DEVICE
Intervention: LaborView Electronic Fetal Monitor
Description: Per LaborView directions, electrode application sites will be prepared to reduce skin impedance, electrodes will be applied to the maternal abdomen and FHR data acquired for comparison with CTG data obtained through the traditional monitoring system. The comparison will be performed off-line.~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus.
Study: NCT03898349

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Annie text messaging system
Description: Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Annie text messaging system with Usual implementation
Description: Three comparison sites received usual implementation of the automated text messaging system Annie only, which involves an orientation/training meeting and the option of attending twice-monthly Annie clinical adoption calls

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Annie text messaging system with Augmented implementation
Description: Four facilities received the automated text messaging system Annie and our augmented implementation strategy. These facilities had regular facilitation calls, a site visit to assist with implementation, and were given the toolkit, in addition to receiving usual implementation assistance
Study: NCT04371445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Ophthalmic Insert
Description: DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care including topical antibiotics.
Study: NCT02477501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: continuous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: continuous infusion
Study: NCT03476083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.
Description: All mothers will receive TDF therapy. However, group A will initiate TDF at the gestational week of 14-16, while group B will initiate TDF at the gestational week of 28. All infants will receive a series of three hepatitis B vaccines (at birth, age of weeks 4 and 24). In addition, the infants in the group B will receive HBIg injection at birth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.
Description: All mothers will receive TDF therapy. However, group A will initiate TDF at the gestational week of 14-16, while group B will initiate TDF at the gestational week of 28. All infants will receive a series of three hepatitis B vaccines (at birth, age of weeks 4 and 24). In addition, the infants in the group B will receive HBIg injection at birth.
Study: NCT02029651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-glove system
Description: Novel rehabilitation system using game for upper extremity rehabilitation for patients with stroke

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional occupational therapy
Description: conventional occupational therapy
Study: NCT03647540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluorescent laparoscopic radical gastrectomy
Description: The gastrectomy for group F would be underwent by the fluorescence laparoscopy. All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional laparoscopic radical gastrectomy
Description: The gastrectomy for group L would be underwent by the laparoscopy.All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
Study: NCT03095066

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786-28
Description: 28 mg of d6-DM and 4.9 mg of Q

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786-28
Description: 28 mg of d6-DM and 4.9 mg of Q

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786-28
Description: 28 mg of d6-DM and 4.9 mg of Q

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786-42.63
Description: 42.63 mg of d6-DM and 4.9 mg of Q

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786-42.63
Description: 42.63 mg of d6-DM and 4.9 mg of Q

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786-42.63
Description: 42.63 mg of d6-DM and 4.9 mg of Q
Study: NCT02945410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric Restriction
Description: Participants will consume 30 kcal/kg FFM/day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Restriction
Description: Participants will consume 30 kcal/kg FFM/day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein
Description: Participants will consume 1.7 g protein/kg BW/day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Protein
Description: Participants will consume 1.7 g protein/kg BW/day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will conduct aerobic exercise designed to expend 15 kcal/kg FFM/day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants will conduct aerobic exercise designed to expend 15 kcal/kg FFM/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Participants will conduct aerobic exercise designed to expend 15 kcal/kg FFM/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D
Description: Participants will be provided calcium and vitamin D supplement in order to maintain calcium and Vitamin D intake constant across all study arms

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and Vitamin D
Description: Participants will be provided calcium and vitamin D supplement in order to maintain calcium and Vitamin D intake constant across all study arms

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium and Vitamin D
Description: Participants will be provided calcium and vitamin D supplement in order to maintain calcium and Vitamin D intake constant across all study arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maltodextrin
Description: Participants will be provided with maltodextrin to supplement the liquid diet in order to meet caloric needs within each study arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin
Description: Participants will be provided with maltodextrin to supplement the liquid diet in order to meet caloric needs within each study arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Participants will be provided with maltodextrin to supplement the liquid diet in order to meet caloric needs within each study arm
Study: NCT02848677

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional counseling
Description: Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: usual care
Description: usual care of hypertensive patients.
Study: NCT04371445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care including topical antibiotics.
Study: NCT02134132

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Gel
Description: Application of platelet gel in patients suffering from diabetic foot ulcers.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients with Diabetic foot ulcer who receive placebo instead of PL Gel.
Study: NCT03780842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA level
Description: A titration protocol will be used for changing NAVA levels. The NAVA level will be reduced to 0,5 cmH2O/µV for 3 minutes as a starting point. Limit peak pressure will be set to 35cmH2O (i.e. according to the standard manufacturer's settings) the maximum pressure that can be delivered to the patient is cut off at 30cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated. Ventilator settings will be according to our standard of care and as following: PEEP between 4 and 7 mmHg, apnea time 2-5 sec, back-up ventilation with a pressure above PEEP between 5 and 15 mmHg and a frequency between 30 and 50 per minute.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 4,0 cmH2O/µV.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA level
Description: A titration protocol will be used for changing NAVA levels. The NAVA level will be reduced to 0,5 cmH2O/µV for 3 minutes as a starting point. Limit peak pressure will be set to 35cmH2O (i.e. according to the standard manufacturer's settings) the maximum pressure that can be delivered to the patient is cut off at 30cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated. Ventilator settings will be according to our standard of care and as following: PEEP between 4 and 7 mmHg, apnea time 2-5 sec, back-up ventilation with a pressure above PEEP between 5 and 15 mmHg and a frequency between 30 and 50 per minute.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 4,0 cmH2O/µV.
Study: NCT01856790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePID closed loop system
Description: Insulin pump controlled by closed loop unit and algorithm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide is a long-acting analog of human glucagon like peptide-1 (GLP-1) that works as a GLP-1 receptor agonist
Study: NCT04133493

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kerecis Omega3 Wound
Description: The intervention group will receive, in addition, a fish skin graft (KerecisTM Omega3 Wound) secured with Steristrips, sutures or staples, covered with a nonadherent dressing (Adaptic, Systagenix, Yorkshire, UK or equivalent), the product bolstered down to the wound bed with a foam dressing (HydraFoam, DermaRite) and hydrogel as needed to retain adequate moisture balance and padded with stretch gauze and self adherent wrap as needed.~The wound will be dressed by the site investigator 1 day a week.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fibracol
Description: The Standard of Care Group will receive Fibracol covered with DSD. Change three times per week
Study: NCT03284762

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban is a direct Factor Xa inhibitor. In this non-interventional setting, the prescription and dosing scheme is up to the treatment physician, however, the recommended dosing scheme is 20mg/day (once daily) or 15 mg/day (once daily) in patients with reduced renal function
Study: NCT00773994

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Velopharyngeal Mechansim
Description: The amount of radiation exposure that you will receive from this procedure is about 0.3 rem to the head and neck, with minimal exposure of the other body areas.
Study: NCT00733109

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excision of the lesion
Description: Surgery with Large Loop Excision of Transformation Zone (LLETZ)
Study: NCT03943524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interax-AI
Description: Interax-AI is a drug interactions detection module for the electronic clinical history software DrApp
Study: NCT02049385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Description: A nondiuretic vasodilator thiazide-related agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04189198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine
Description: Supraclavicular block with 30 ml articaine 2%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Supraclavicular block with 30 ml bupivacaine 0.5%
Study: NCT01003691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RN6G
Description: Intravenous, multiple dose, dose ranging from 5 mg/kg up to a maximum of 15 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous, multiple dose with experimental dose
Study: NCT02887508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HINTS Intervention
Description: HINTS is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on sexual risk reduction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Control
Description: The Healthy Living Control is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on non-sexual health topics.
Study: NCT04480905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic tape
Description: The dynamic tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
Study: NCT00733109

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Follow-up for spontaneous regression of the lesion
Description: Follow-up at last 12 months
Study: NCT01661712

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical stimulation
Description: Transcutaneous electrical stimulation (one night of electrical current titrated according to skin sensation)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation for one night (no electrical stimulation)
Study: NCT03314727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High salt (NaCl) intake
Description: Participants are asked to consume two high sodium-containing soups while monitoring their serum osmolarity levels